Clinical trials: Advanced Cancers of the Prostate
Advanced Solid Tumor
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091)…
- Trial name
- NCT05932862
- Testing
- XL309, Olaparib
- Where
- 16 sites in United States
- Volunteers
- 429 people
- Sponsor
- Exelixis
Adenocarcinoma of the Prostate
TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer
This is an open-label, single arm, two part adaptive design phase II trial of Olaparib in patients with advanced castration resistant prostate cancer.
- Trial name
- TOPARP (NCT01682772)
- Testing
- Olaparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body…
- Conditions
- Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04947254
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer (NSCLC), Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
- Conditions
- Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
- Trial name
- NCT07181473
- Testing
- TJ101
- Where
- 7 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Phrontline Biopharma
Advanced Prostate Cancer
Study of HPN424 in Patients With Advanced Prostate Cancer
An open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapy
- Trial name
- NCT03577028
- Testing
- HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 104 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer of the Prostate
Eligard Observational Registry for Patients With Prostate Cancer
The objective of this registry is to collect data on patient demographics, medical history, change in prostate, bone and overall health of the patients receiving androgen ablation treatment using Eligard.
- Trial name
- NCT00992251
- Where
- 36 sites in Canada
- Volunteers
- 354 people
- Sponsor
- CMX Research
Advanced Prostate Cancer
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
The study is being conducted to evaluate the the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of HRS-4357 injection in adult patients with advanced prostate cancer.
- Trial name
- NCT06006104
- Testing
- HRS-4357 injection
- Volunteers
- 49 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostatic Neoplasms
Phase II Study of BI 2536 in Prostate Cancer
A study to investigate the activity of BI 2536 in Prostate Cancer
- Trial name
- NCT00706498
- Testing
- BI 2536
- Where
- 6 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Prostate Cancer
Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00483561
- Testing
- Gefitinib plus etoposide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either…
- Trial name
- MEVPRO-1 (NCT06551324)
- Testing
- PF-06821497, Docetaxel, Enzalutamide
- Where
- 224 sites in United States, Argentina and 21 more
- Volunteers
- 609 people
- Sponsor
- Pfizer
Triple Negative Breast Cancer, HER2-negative Breast Cancer
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
- Conditions
- Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- NCT06999187
- Testing
- DR-0202
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Dren Bio
Neoplasms, Neoplasm Metastasis
A Study of LY3022855 In Participants With Breast or Prostate Cancer
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments.
- Trial name
- NCT02265536
- Testing
- LY3022855
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
Prostate Cancer
A Study Into the Effectivity and Safety of Firmagon, Prescribed for Treatment of Patients With Advanced Prostate Cancer
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival.
- Trial name
- FAST-NL (NCT01215526)
- Where
- 47 sites in Netherlands
- Volunteers
- 274 people
- Sponsor
- Ferring Pharmaceuticals
Breast Cancer, Ovarian Cancer
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
The goal of this interventional clinical trial is to learn about TNG348, a ubiquitin specific peptidase 1 (USP1) inhibitor, alone and in combination with olaparib in patients with BRCA 1/2 mutant or HRD+ solid tumors.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer
- Trial name
- NCT06065059
- Testing
- TNG348, Olaparib
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Tango Therapeutics, Inc.
Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
- Trial name
- NCT05914116
- Testing
- DB-1311, Lopinavir and Ritonavir Tablets, itraconazole
- Where
- 107 sites in United States, Australia and 2 more
- Volunteers
- 862 people
- Sponsor
- DualityBio Inc.
Fasting, Prostatic Neoplasms
Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer
The aim of this trial is a first evaluation of the effectiveness of intermittent fasting as a supplementary therapy in patients with CRPC or hormone-sensitive prostate cancer with high metastatic load (1≥ visceral and ≥4 osseous…
- Trial name
- NCT02710721
- Testing
- Fasting, Control
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Charite University, Berlin, Germany
Prostate Cancer
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003633
- Testing
- docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center